Healthcare 1 April 2026 - 22 May 2026

Dentsply Sirona stock lifts after holiday weekend, but turnaround questions remain
···

Dentsply Sirona stock lifts after holiday weekend, but turnaround questions remain

Dentsply Sirona shares closed Friday at $10.21, up 2.8% on the day and 1.4% for the week, after touching a low of $9.40 on Tuesday. U.S. markets are closed for Memorial Day on Monday, with the next scheduled company update at the Stifel Jaws & Paws conference on May 27. First-quarter net sales were flat at $880 million, with a GAAP net loss per share of 5 cents. Constant-currency sales dropped 6.7%.
May 24, 2026
Serve Robotics Stock Drops Before Long Weekend, Hospital Project Still Needs Funding
····

Serve Robotics Stock Drops Before Long Weekend, Hospital Project Still Needs Funding

Serve Robotics Inc. shares fell 1.25% to $8.70 Friday, underperforming a record-setting Dow, then ticked up to $8.73 after hours. Volume reached 3.84 million shares, with a market value near $673 million. Investors weighed rapid revenue growth and a new hospital robotics push against funding and execution risks ahead of the Memorial Day market holiday.
May 22, 2026
Atrium Therapeutics Stock Climbs: The Key FDA Filing Investors Are Watching Now
···

Atrium Therapeutics Stock Climbs: The Key FDA Filing Investors Are Watching Now

Atrium Therapeutics shares climbed 1.9% to $12.96 Thursday, valuing the company at about $222 million. The RNA drug developer expects to submit its first IND for ATR 1072, targeting PRKAG2 syndrome, in the second half of 2026. Atrium reported $267.8 million in cash at March 31, with all programs still preclinical. Leerink Partners initiated coverage last week with an outperform rating and $25 price target.
May 21, 2026
RADX Shares Slip Ahead of Cancer-Imaging Update
···

RADX Shares Slip Ahead of Cancer-Imaging Update

Radiopharm Theranostics’ U.S.-listed shares last traded at $4.52, down 1.3% on volume of 325, as investors awaited new data from its lead cancer-imaging program. The company’s most recent update was a May 14 Zacks report, with topline Phase 2 trial results for RAD101 expected around the end of June. Radiopharm reported A$19.2 million in cash as of March 31.
May 21, 2026
Advanced Medical Solutions dives as TA Associates deal collapses
···

Advanced Medical Solutions dives as TA Associates deal collapses

Advanced Medical Solutions Group shares fell 16.8% to 204.5 pence by late morning Monday after TA Associates said it would not make a takeover offer. The stock had traded as high as 247 pence last week on deal speculation. TA’s formal withdrawal restricts it from bidding again for six months unless exceptions apply. Advanced Medical Solutions reported record 2025 revenue of £228.9 million in March.
May 18, 2026
Spire Healthcare Group PLC Shares Surge as Toscafund’s £1bn Takeover Bid Revives Sale Talks
···

Spire Healthcare Group PLC Shares Surge as Toscafund’s £1bn Takeover Bid Revives Sale Talks

Toscafund has made a non-binding cash proposal of 250 pence per share for Spire Healthcare, valuing the company at about £1.01 billion. Spire’s board said it would be minded to recommend the offer if Toscafund makes it firm by the June 11 UK Takeover Panel deadline. Spire shares rose 42% to 213.36 pence after the news. Talks remain at an early stage, with Toscafund conducting due diligence.
May 14, 2026
GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight
···

GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight

A U.S. judge dismissed Acuitas Therapeutics’ attempt to clear Pfizer and BioNTech’s Comirnaty vaccine of GSK patent claims, citing lack of jurisdiction, Bloomberg Law reported Friday. The decision keeps the focus on GSK’s main Delaware lawsuit alleging Comirnaty infringes mRNA-vaccine patents. Pfizer has pledged to defend its position. The ruling does not address whether infringement occurred.
May 9, 2026
Star Health’s Cheaper Insurance Bet Meets Claims Scrutiny as Payouts Jump
···

Star Health’s Cheaper Insurance Bet Meets Claims Scrutiny as Payouts Jump

Star Health will launch two low-cost health insurance products for smaller Indian cities this fiscal year, aiming for Rs 24,000 crore in gross written premium by FY27. Claim payouts in Andhra Pradesh and Telangana rose 24% in FY26. The company reported Rs 911 crore profit after tax for FY26, with a combined ratio of 98.8%. A Kerala consumer panel faulted Star Health over a COVID-era claim denial.
May 7, 2026
BioNTech Stock Faces A Hard Cancer Pivot Test After Q1 Loss Widens And 1,860 Jobs Are Hit
···

BioNTech Stock Faces A Hard Cancer Pivot Test After Q1 Loss Widens And 1,860 Jobs Are Hit

BioNTech’s first-quarter revenue dropped to €118.1 million, with net loss widening to €531.9 million. The company will exit sites in Germany and Singapore, affecting up to 1,860 jobs, and plans a $1 billion share buyback. Cash reserves stood at €16.8 billion at the end of March. BioNTech maintained its 2026 revenue outlook and is focusing on late-stage cancer drugs.
May 5, 2026
4DMedical Stock Faces Its Next Big Test After GSK Deal, ASX 200 Entry
···

4DMedical Stock Faces Its Next Big Test After GSK Deal, ASX 200 Entry

4DMedical shares last traded at A$4.02, valuing the lung-imaging software firm at about A$2.37 billion after a year of sharp price swings. The company reported 86,200 scans in the March quarter, up 79%, and began a one-year research contract with GSK on May 1. CT:VQ software adoption expanded to five U.S. academic centers, with Mayo Clinic evaluating. 4DMedical raised A$233 million this year and moved into the S&P/ASX 200.
May 3, 2026
GSK Shares Bounce After Shingrix Surge, But Investors Spot One Big Catch
···

GSK Shares Bounce After Shingrix Surge, But Investors Spot One Big Catch

GSK shares rose 1.04% to 1,938 pence in London Thursday after a first-quarter profit beat, following a 5.42% drop Wednesday. Quarterly turnover climbed 5% to £7.63 billion, with Shingrix vaccine sales up 20% to £1 billion, beating forecasts. GSK held its 2026 guidance and did not raise its outlook. Investors questioned whether the earnings beat was driven by one-off factors.
April 30, 2026
Reckitt Benckiser Durex Headache Deepens as China Price Scare Follows Weak Quarter
···

Reckitt Benckiser Durex Headache Deepens as China Price Scare Follows Weak Quarter

Reckitt warned of lower first-half margins after missing first-quarter sales growth forecasts, citing high oil prices, Russia sanctions, and weak cold-and-flu demand. A viral scare over condom price hikes in China, a key growth market, followed news that supplier Karex may raise prices up to 30% if Iran-war disruptions persist. Reckitt’s shares fell as much as 7% after Wednesday’s update.
April 25, 2026
ConvaTec Shares Drop Again as Wound-Care Warning Puts 2026 Growth Plan in Focus
···

ConvaTec Shares Drop Again as Wound-Care Warning Puts 2026 Growth Plan in Focus

Convatec shares fell 1.69% to £2.21 in London Friday, closing nearly 30% below their 52-week high as investors reacted to weakness in the wound-care market. The drop followed Coloplast’s cut to its 2025/26 outlook and a DKK 3 billion impairment on its Kerecis business. Convatec expects InnovaMatrix revenue to fall to $20 million in 2026 due to U.S. Medicare changes.
April 24, 2026
GSK Shares Slip as U.S.-UK Drug Deal Eases Tariff Threat Before April Results
···

GSK Shares Slip as U.S.-UK Drug Deal Eases Tariff Threat Before April Results

GSK’s U.S.-listed shares slipped 0.7% to $56.29 after a U.S.-UK medicines pact guaranteed zero U.S. tariffs on UK-made drugs for three years, in exchange for higher NHS prices and changes to NICE drug assessments. The deal comes as Trump imposed 100% tariffs on patented drugs not made in the U.S. or covered by pricing agreements. GSK will report first-quarter results April 29. AstraZeneca has similar tariff protection.
April 6, 2026
GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake
···

GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake

GSK completed a reshaping of ViiV Healthcare’s ownership on April 1, with Shionogi raising its stake to 21.7% after Pfizer exited the HIV-focused venture. ViiV issued new shares to Shionogi for $2.125 billion and cancelled Pfizer’s holding. GSK retained a 78.3% majority and took a $250 million special dividend. The deal extinguished a put option liability tied to the old structure.
April 2, 2026
GSK plc Completes ViiV Healthcare Shake-Up as Pfizer Exits, Shionogi Lifts Stake
···

GSK plc Completes ViiV Healthcare Shake-Up as Pfizer Exits, Shionogi Lifts Stake

Shionogi increased its stake in ViiV Healthcare to 21.7% as Pfizer exited, leaving GSK with a 78.3% majority. ViiV issued new shares to Shionogi for $2.125 billion and paid Pfizer $1.875 billion. GSK received a $250 million special dividend and removed an accounting liability tied to Pfizer’s exit. The transaction followed Chinese approval of GSK’s asthma drug Exdensur.
April 1, 2026
1 2 3 … 5

Stock Market Today

  • HSBC's AI Strategy Influences FTSE 100 Banking Sector Discussion
    May 24, 2026, 2:47 PM EDT. HSBC's integration of artificial intelligence (AI) into its stock market strategy is sparking new conversations among FTSE 100 banking stocks. The bank's focus on AI-driven investment techniques highlights an industry trend toward technological adoption to enhance trading and risk management. This shift could impact investor sentiment and valuations in the competitive UK banking sector. HSBC's approach showcases how major financial institutions are leveraging AI to refine stock selection and portfolio management, emphasizing the growing role of tech innovation in traditional banking frameworks.